ZURICH, June 22 (Reuters) - Novartis aims to help manufacture more than 50 million doses of BioNTech's COVID-19 vaccine in 2021 at its Stein, Switzerland fill-and-finish facility, the Swiss drugmaker said, after the European Union's drug regulator approved the bottling plant. (Reporting by John Miller Editing by Chris Reese)
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
92.58 CHF | +0.28% | +5.09% | +8.93% |
May. 10 | Novartis’ Scemblix Gets Third US FDA Breakthrough Therapy Designation | MT |
May. 10 | Novartis Gets FDA Breakthrough Therapy Designation for Scemblix | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+8.93% | 208B | |
+30.38% | 684B | |
+29.54% | 568B | |
-4.36% | 361B | |
+19.30% | 329B | |
+3.73% | 284B | |
+16.40% | 240B | |
-7.53% | 200B | |
+7.68% | 166B | |
-2.71% | 159B |
- Stock Market
- Equities
- NOVN Stock
- News Novartis AG
- Novartis : aims to bottle more than 50 mln doses of BioNTech COVID-19 vaccine in 2021